Neoadjuvant HER2+ | Specialty

Dr. Wesolowski on the Potential Future Utility of Trastuzumab Deruxtecan in HER2+ Breast Cancer

May 10th 2021

Robert Wesolowski, MD, discusses the potential future utility of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

Neratinib Shows Numeric OS Benefit, Trend Toward Improved CNS Outcomes in Early-Stage HER2+ Breast Cancer

May 10th 2021

Although fewer deaths were reported with neratinib in patients with HER2-positive breast cancer treated on the phase 3 ExteNET trial, the agent was not found to result in a significant improvement in overall survival after 8 years of follow-up.

High-Grade ILD Prevention With Trastuzumab Deruxtecan Includes Early Detection, Optimal Management in HER2+ Metastatic Breast Cancer

May 8th 2021

Effective early detection and optimal management are critical in preventing high-grade interstitial lung disease, a treatment-related adverse effect of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive metastatic breast cancer.

HER2+ Breast Cancer With Immune-Related Gene Signatures May Be Eligible for De-Escalation Approaches

May 8th 2021

Distinct gene signatures, with the exception of estrogen receptor signaling and BRCAness, are associated with pathologic complete response and invasive disease-free survival, in patients with HER2-positive breast cancer who received trastuzumab and pertuzumab alone or in combination with paclitaxel.

Dr. Powell on the Risk of ILD with Trastuzumab Deruxtecan in HER2+ Breast Cancer

May 8th 2021

Charles Powell, MD, MBA, discusses the risk of interstitial lung disease in patients with HER2-positive metastatic breast cancer treated with trastuzumab deruxtecan.

Dr. Conte on Outcomes With 1 Year Vs 9 Weeks of Adjuvant Trastuzumab in HER2+ Breast Cancer

May 7th 2021

Pier Franco Conte, MD, discusses long-term outcomes with 1 year vs 9 weeks of treatment with adjuvant trastuzumab in patients with HER2-positive early breast cancer.

KATHERINE and FeDeriCa Trials Shift Standards in Early-Stage HER2+ Breast Cancer

May 6th 2021

Olwen Hahn, MD, discusses the clinical significance of the KATHERINE and FeDeriCa trials in the treatment of patients with early-stage HER2-postive breast cancer.

Dr. Hahn on the Impact of Trastuzumab Emtansine in HER2+ Breast Cancer

May 3rd 2021

Olwen Hahn, MD, discusses the impact of trastuzumab emtansine on the treatment of patients with HER2-positive breast cancer.

Dr. Hahn on the Convenience of Subcutaneous Trastuzumab/Pertuzumab in HER2+ Breast Cancer

April 30th 2021

Olwen Hahn, MD, discusses the convenience of the fixed-dose combination of trastuzumab and pertuzumab in a subcutaneous formulation in HER2-positive breast cancer.

Dr. Meisel on Sequencing Therapies in Metastatic HER2+ Breast Cancer

April 21st 2021

Jane L. Meisel, MD, discusses sequencing therapies for patients with metastatic HER2-positive breast cancer.